AstraZeneca Exanta Risk Plan Not Sufficient To Allay Liver Toxicity Concerns
Executive Summary
AstraZeneca's proposed Exanta risk management plan is not sufficient to alleviate liver toxicity concerns with the anticoagulant, FDA's Cardiovascular & Renal Drugs Advisory Committee said